Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos
IF 1.6 4区 医学Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
M.N. Acar Tayyar , M.Ö. Tamam , G.B. Babacan , M.C. Şahin , H. Özçevik , S. Şengiz Erhan , A.E. Öztürk
{"title":"Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos","authors":"M.N. Acar Tayyar , M.Ö. Tamam , G.B. Babacan , M.C. Şahin , H. Özçevik , S. Şengiz Erhan , A.E. Öztürk","doi":"10.1016/j.remn.2024.500080","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [<sup>18</sup>F]FDG PET/CT and to investigate its impact on survival.</div></div><div><h3>Methods</h3><div>Pretreatment metabolic parameters measured by [<sup>18</sup>F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated.</div></div><div><h3>Results</h3><div>Among the 117 patients, 17.1% were HER2-positive (HER2<sup>+</sup>), and 82.9% were HER2-negative (HER2<sup>−</sup>). There was no significant association between PET/CT parameters in the HER2<sup>+</sup> and HER2<sup>−</sup> patient groups. HER2<sup>+</sup> patients had higher 1- and 3-year survival expectations than HER2<sup>−</sup> patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG.</div></div><div><h3>Conclusion</h3><div>This study showed no association between HER2 expression and [<sup>18</sup>F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500080"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Medicina Nuclear E Imagen Molecular","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253654X24001136","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [18F]FDG PET/CT and to investigate its impact on survival.
Methods
Pretreatment metabolic parameters measured by [18F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated.
Results
Among the 117 patients, 17.1% were HER2-positive (HER2+), and 82.9% were HER2-negative (HER2−). There was no significant association between PET/CT parameters in the HER2+ and HER2− patient groups. HER2+ patients had higher 1- and 3-year survival expectations than HER2− patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG.
Conclusion
This study showed no association between HER2 expression and [18F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.
期刊介绍:
The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members.
The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles.